Certara, Inc. (CERT)
|Net Income (ttm)||-49.40M|
|Trading Day||April 22|
|Day's Range||28.05 - 30.55|
|52-Week Range||24.58 - 41.79|
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it will release preliminary financial results for the first quarter of 2021 after market close on May 6, 2021.
PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the closing of its underwritten public offering of its common stock at a public offering price of $25.00 per share.
PRINCETON, N.J.--(BUSINESS WIRE)--Certara announced the pricing of its public offering of common stock by certain existing stockholders at a price of $25.00 per share.
Certara Adopts TrialAssure ANONYMIZE Solution to Speed Life Science Industry Need to Meet Regulatory Requirements for...
PRINCETON, N.J.--(BUSINESS WIRE)-- #anonymization--TrialAssure® – a leading, global software company advancing clinical trial disclosure, data sharing, and transparency – has announced today that Certar...
PRINCETON, N.J.--(BUSINESS WIRE)--Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it is set to join the Russell 1000® Index.
Certara Reports Preliminary Fourth Quarter and Full Year 2020 Results and Issues Full Year 2021 Guidance
PRINCETON, N.J.--(BUSINESS WIRE)--Certara, a global leader in biosimulation, today reported its preliminary results for the fourth quarter and full year ending December 31, 2020.
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that William Feehery, CEO and Andrew Schemick, CFO will virtually present at the Barclays Global Healthcare Conference.
The Year 2020 Marks the 7th Consecutive Year Certara Customers Received 90 Percent of US FDA Novel Drug and Biologic ...
PRINCETON, N.J.--(BUSINESS WIRE)--2020 was the 7th consecutive year where 90% of new drug & biologic approvals by the FDA were received by Certara's customers.
PRINCETON, N.J.--(BUSINESS WIRE)--Certara will release preliminary financial results for the fourth quarter and full year of 2020 after the market close on Thursday, March 4, 2021.
PRINCETON, N.J.--(BUSINESS WIRE)-- #Biologics--Certara, Inc. today announced the release of version 20 of its Simcyp™ Physiologically-based Pharmacokinetic (PBPK) Simulator platform.
STOCKHOLM, Dec. 17, 2020 /PRNewswire/ -- EQT is pleased to announce that on 10 December 2020, the EQT VII portfolio company Certara, Inc. ("Certara"), a global leader in biosimulation based on 2019 reve...
Certara Announces Closing of Its Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Pur...
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced that it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share.
Hot initial public offerings aren't just for technology companies.
Drug Software Firm Certara Expands IPO to Raise $668 Million
Dec.11 -- Certara Inc., a maker of drug-development software, upsized its initial public offering and priced it above the marketed range to raise $668 million, adding to the red-hot week for U.S. listin...
Certara CEO on strong IPO debut
CNBC's "Squawk Alley" team discusses Certara's IPO with CEO William Feehery.
Four companies increased the size of their deals.
PRINCETON, N.J.--(BUSINESS WIRE)--Certara today announced the pricing of its upsized initial public offering of 29,055,000 shares of its common stock at $23.00 per share.
Certara has filed proposed terms for its $500 million U.S. IPO.
Certara, which provides biosimulation software and services used for drug development, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.u00a0However, this is lik...
Certara, Inc. has filed to go public with an IPO on the NASDAQ.
Certara accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. Biosimulation is a powerful technology used to conduct virtual trials using virtual patients to predict how drugs behave in different individuals. Biopharmaceutical companies use our proprietary biosimulation software throughout drug discovery and development to inform critical decisions that not only save significant time and money but also advance drug safety and efficacy, improving millions of lives e... [Read more...]
|IPO Date |
Dec 11, 2020
William F. Feehery
|Stock Exchange |
|Ticker Symbol |
In 2020, Certara's revenue was $243.53 million, an increase of 16.79% compared to the previous year's $208.51 million. Losses were -$49.40 million, 453.4% more than in 2019.
According to 5 analysts, the average rating for Certara stock is "Buy." The 12-month stock price forecast is 36.00, which is an increase of 21.09% from the latest price.